Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
After finishing at $0.6 in the prior trading day, Outlook Therapeutics Inc (NASDAQ: OTLK) closed at $0.59, down -2.37%. In other words, the price has decreased by -$2.37 from its previous closing price. On the day, 4.43 million shares were traded. OTLK stock price reached its highest trading level at $0.646 during the session, while it also had its lowest trading level at $0.5825.
Ratios:
Our goal is to gain a better understanding of OTLK by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.54 and its Current Ratio is at 0.67.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OTLK now has a Market Capitalization of 37827496 and an Enterprise Value of 59939108. For the stock, the TTM Price-to-Sale (P/S) ratio is 25.66. Its current Enterprise Value per Revenue stands at 42.404 whereas that against EBITDA is -0.895.
Stock Price History:
The Beta on a monthly basis for OTLK is 0.13, which has changed by -0.7423581 over the last 52 weeks, in comparison to a change of 0.19362879 over the same period for the S&P500. Over the past 52 weeks, OTLK has reached a high of $3.39, while it has fallen to a 52-week low of $0.50. The 50-Day Moving Average of the stock is -63.22%, while the 200-Day Moving Average is calculated to be -63.18%.
Shares Statistics:
The stock has traded on average 6.46M shares per day over the past 3-months and 22915000 shares per day over the last 10 days, according to various share statistics. A total of 43.48M shares are outstanding, with a floating share count of 41.98M. Insiders hold about 34.52% of the company’s shares, while institutions hold 6.31% stake in the company. Shares short for OTLK as of 1765756800 were 3082849 with a Short Ratio of 0.48, compared to 1763078400 on 4060839. Therefore, it implies a Short% of Shares Outstanding of 3082849 and a Short% of Float of 6.7.
Earnings Estimates
The market rating for Outlook Therapeutics Inc (OTLK) is a result of the insights provided by 3.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.16, with high estimates of -$0.07 and low estimates of -$0.26.
Analysts are recommending an EPS of between -$0.28 and -$0.99 for the fiscal current year, implying an average EPS of -$0.67. EPS for the following year is -$0.41, with 3.0 analysts recommending between -$0.19 and -$0.84.
Revenue Estimates
For the next quarter, 4 analysts are estimating revenue of $4.1M. There is a high estimate of $9M for the next quarter, whereas the lowest estimate is $1.5M.
A total of 4 analysts have provided revenue estimates for OTLK’s current fiscal year. The highest revenue estimate was $46.02M, while the lowest revenue estimate was $8.6M, resulting in an average revenue estimate of $21.14M. In the same quarter a year ago, actual revenue was $1.41MBased on 4 analysts’ estimates, the company’s revenue will be $48.59M in the next fiscal year. The high estimate is $132.65M and the low estimate is $17.4M.
